# US 2026/0060978 A1 · Methods of treating rheumatic diseases using trimetazidine-based compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0060978 A1
- Document ID: US20260060978A1
- Status: Published application
- Kind: A1
- Application number: 19/197,314
- Filed: 2025-05-02
- Published: 2026-03-05
- Earliest claimed: 2018-10-17
- Assignees: Imbria Pharmaceuticals, Inc.
- Applicants: Imbria Pharmaceuticals, Inc.
- Inventors: Andrew D. Levin; David-Alexandre Gros; Jaikrishna Patel
- Web page: https://patentgrep.com/patent/US20260060978A1

## CPC

- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/336: having three-membered rings, e.g. oxirane, fumagillin
- A61K 31/4458: only substituted in position 2, e.g. methylphenidate
- A61K 31/4965: Non-condensed pyrazines
- A61K 31/497: containing further heterocyclic rings
- A61K 47/55: the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 17/06: Antipsoriatics
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides compositions and methods for treating a subject having a rheumatic condition.

## Claims

### Claim at position 1

1-38. (canceled)

### Claim 39

A method of treating a rheumatic disease, disorder, or condition in a subject, the method comprising providing to a subject having a rheumatic disease, disorder, or condition a composition comprising a compound represented by formula (X):

### Claim 40 (depends on 39)

The method of claim 39, wherein the rheumatic disease, disorder, or condition is selected from the group consisting of acute kidney injury, alcoholic cardiomyopathy, angina, ankylosing spondylitis, autoimmune-related lung disease, Behcet's Disease, bursitis, cachexia, cardiac fibrosis, chemotherapy chronic fatigue syndrome, claudication, contrast nephropathy, cyanotic heart disease, dermatomyositis, dilated cardiomyopathy, disequilibrium, fibromyalgia, frailty, gout, Gulf War syndrome, heart failure, hypertrophic cardiomyopathy, induced nephropathy, infectious arthritis, inflammatory arthritis, inflammatory eye disease, inflammatory myositis, ischemic cardiomyopathy, juvenile idiopathic arthritis, left ventricular dysfunction, lupus, muscle myopathy, myofascial pain syndrome, myositis, osteoarthritis, osteonecrosis of the jaw, osteoporosis, polymyalgia rheumatica, polymyositis, psoriatic arthritis, pulmonary arterial hypertension, pulmonary fibrosis, a rare muscle disease, rheumatoid arthritis, sarcoidosis, sarcopenia, scleroderma, Sjogren's syndrome, tendinitis, tinnitus, vasculitis, and vertigo.

### Claim 41 (depends on 39)

The method of claim 39, wherein the composition is administered in a single unit dose.

### Claim 42 (depends on 39)

The method of claim 39, wherein the composition is administered in a dose comprising multiple units.

### Claim 43 (depends on 39)

The method of claim 39, wherein the composition is formulated for oral administration.

### Claim 44 (depends on 39)

The method of claim 39, wherein the composition is formulated for intravenous administration.

### Claim 45

A method of treating a rheumatic disease, disorder, or condition in a subject, the method comprising providing to a subject having a rheumatic disease, disorder, or condition a composition comprising a compound represented by formula (X):

### Claim 46 (depends on 45)

The method of claim 45, wherein the rheumatic disease, disorder, or condition is selected from the group consisting of acute kidney injury, alcoholic cardiomyopathy, angina, ankylosing spondylitis, autoimmune-related lung disease, Behcet's Disease, bursitis, cachexia, cardiac fibrosis, chemotherapy chronic fatigue syndrome, claudication, contrast nephropathy, cyanotic heart disease, dermatomyositis, dilated cardiomyopathy, disequilibrium, fibromyalgia, frailty, gout, Gulf War syndrome, heart failure, hypertrophic cardiomyopathy, induced nephropathy, infectious arthritis, inflammatory arthritis, inflammatory eye disease, inflammatory myositis, ischemic cardiomyopathy, juvenile idiopathic arthritis, left ventricular dysfunction, lupus, muscle myopathy, myofascial pain syndrome, myositis, osteoarthritis, osteonecrosis of the jaw, osteoporosis, polymyalgia rheumatica, polymyositis, psoriatic arthritis, pulmonary arterial hypertension, pulmonary fibrosis, a rare muscle disease, rheumatoid arthritis, sarcoidosis, sarcopenia, scleroderma, Sjogren's syndrome, tendinitis, tinnitus, vasculitis, and vertigo.

### Claim 47 (depends on 45)

The method of claim 45, wherein the composition is administered in a single unit dose.

### Claim 48 (depends on 45)

The method of claim 45, wherein the composition is administered in a dose comprising multiple units.

### Claim 49 (depends on 45)

The method of claim 45, wherein the composition is formulated for oral administration.

### Claim 50 (depends on 45)

The method of claim 45, wherein the composition is formulated for intravenous administration.
